验证[18F]FLT作为不依赖灌注的影像生物标志物用于接受EGFR酪氨酸激酶抑制剂治疗的EGFR突变NSCLC患者的肿瘤反应评估
本研究纳入6例具有活化EGFR突变的转移性NSCLC患者,在TKI(厄洛替尼或吉非替尼)治疗前及治疗后7天和28天行[15O]H2O和[18F]FLT PET/CT,参数分析显示[18F]FLT V T的体素分布向低V T类别偏移,而灌注及其空间分布变化极小,提示[18F]FLT可能是不依赖灌注的PET示踪剂用于测量肿瘤反应。
要点
- 共评估17次灌注和18次[18F]FLT PET/CT扫描,全部病灶平均灌注为0.53 ± 0.26 mL cm-3 min-1,平均[18F]FLT V T为4.25 ± 1.71 mL cm-3。
- 多参数分析显示体素分布偏移,V T从平均≥77%体素分类为高V T类别变为≥85%体素分类为低V T类别,该偏移在治疗后7天最明显,之后相对相似。
- 灌注及其空间分布的变化极小,提示[18F]FLT摄取变化独立于灌注变化。
核心结论
- 本研究表明[18F]FLT可能是不依赖灌注的PET示踪剂,用于测量肿瘤反应,因为[18F]FLT摄取的参数变化独立于灌注变化。
研究设计与样本
- 纳入6例具有活化EGFR突变的转移性NSCLC患者,在TKI(厄洛替尼或吉非替尼)治疗前及治疗后7天和28天行[15O]H2O和[18F]FLT PET/CT扫描。
- 采用参数分析生成灌注([15O]H2O)和增殖([18F]FLT V T)的定量3D图像,并使用单一全局阈值对所有扫描和受试者进行多参数分类。
- 共评估17次灌注和18次[18F]FLT PET/CT扫描。
主要发现
- 全部病灶平均灌注为0.53 ± 0.26 mL cm-3 min-1,平均[18F]FLT V T为4.25 ± 1.71 mL cm-3。
- 多参数分析提示体素分布偏移,V T从平均≥77%体素分类为高V T类别变为≥85%体素分类为低V T类别。
- 该偏移在治疗后7天最明显,之后相对相似;灌注及其空间分布的变化极小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) was proposed as an imaging biomarker for the assessment of in vivo cellular proliferation with positron emission tomography (PET). The current study aimed to validate [18F]FLT as a perfusion-independent PET tracer, by gaining insight in the intra-tumoural relationship between [18F]FLT uptake and perfusion in non-small cell lung cancer (NSCLC) patients undergoing treatment with a tyrosine kinase inhibitor (TKI). Six patients with metastatic NSCLC, having an activating epidermal growth factor receptor (EGFR) mutation, were included in this study. Patients underwent [15O]H2O and [18F]FLT PET/CT scans at three time points: before treatment and 7 and 28 days after treatment with a TKI (erlotinib or gefitinib). Parametric analyses were performed to generate quantitative 3D images of both perfusion measured with [15O]H2O and proliferation measured with [18F]FLT volume of distribution (V T ). A multiparametric classification was performed by classifying voxels as low and high perfusion and/or low and high [18F]FLT V T using a single global threshold for all scans and subjects. By combining these initial classifications, voxels were allocated to four categories (low perfusion-low V T , low perfusion-high V T , high perfusion-low V T and high perfusion-high V T ). RESULTS: A total of 17 perfusion and 18 [18F]FLT PET/CT scans were evaluated. The average tumour values across all lesions were 0.53 ± 0.26 mL cm- 3 min- 1 and 4.25 ± 1.71 mL cm- 3 for perfusion and [18F]FLT V T , respectively. Multiparametric analysis suggested a shift in voxel distribution, particularly regarding the V T : from an average of ≥ 77% voxels classified in the "high V T category" to ≥ 85% voxels classified in the "low V T category". The shift was most prominent 7 days after treatment and remained relatively similar afterwards. Changes in perfusion and its spatial distribution were minimal. CONCLUSION: The present study suggests that [18F]FLT might be a perfusion-independent PET tracer for measuring tumour response as parametric changes in [18F]FLT uptake occurred independent from changes in perfusion. TRIAL REGISTRATION: Nederlands Trial Register (NTR), NTR3557 . Registered 2 August 2012.
引用
- Iqbal R, Kramer GM, Frings V, et al. Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018. PMID: 29594931. doi:10.1186/s13550-018-0376-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。